1. Japan Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
JSR Corporation

JSR Corporation

4185.T
JSR CorporationJP flagTokyo Stock Exchange
4,340.00
JPY
+5.00
- -
8,680.00Market Cap
JSR Corporation
4185.T
(Tokyo Stock Exchange)

Recent

price

4,340.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
1,420.91
1,270.02
1,397.12
1,450.62
1,547.49
1,661.96
1,731.36
1,700.98
1,736.17
1,895.88
2,238.63
2,179.53
1,452.26
1,585.91
1,957.23
- -
1,916.13
Revenue per Share
56.36
55.86
113.07
109.46
126.13
106.1
128.19
105.87
135.17
149.31
140.62
104.38
-256.73
173.49
75.56
- -
7.36
Basic EPS, GAAP
136.73
240.16
222.53
120.13
198.78
149.52
220.58
211.7
50.73
28.24
-23.82
47.46
70.74
-136.47
-9.25
- -
-24.12
Free Cash Flow per Basic Share
32.14
28.99
29.05
32
33.16
35.67
39.15
45.05
50.06
50
55.02
60.27
59.98
64.98
70.8
- -
34.99
Dividend per Share
974.82
1,012.18
1,098.02
1,187.29
1,151.09
1,234.71
1,347.43
1,370.02
1,487.59
1,596.41
1,694.02
1,812.43
1,518.75
1,658.97
1,494.87
- -
1,497.55
Book Value per Share
948.33
1,002.38
1,061.48
1,149.03
1,288.96
1,390.95
1,501.27
1,532.27
1,599.35
1,715.67
1,658.96
1,677.43
1,382.85
1,267.48
958.62
- -
959.3
Tangible Book Value per Share
248
244
244
241
240
237
233
227
224
223
221
217
215
215
209
208
208
Basic Weighted Avg Shares
352,502
310,183
340,665
349,946
371,487
394,309
404,073
386,709
388,455
421,930
495,354
471,967
312,000
340,997
408,880
- -
397,766
Sales/Revenue/Turnover
8.61
6.52
11.48
10.28
9.48
9.15
9.42
8.9
9.08
10.25
9.03
6.95
11.19
12.79
7.16
- -
2.49
Operating Margin (%)
24,833
22,379
19,245
17,783
19,232
18,095
17,406
18,508
14,758
16,973
21,842
26,359
29,477
22,482
28,425
- -
31,384
Depreciation Expense
13,981
13,644
27,570
26,407
30,278
25,172
29,918
24,068
30,243
33,230
31,116
22,604
-55,155
37,303
15,784
- -
1,528
Net Income, GAAP
29.51
29.6
31.95
35.85
29.3
34.53
28.99
18.4
20.31
24.3
23.67
21.02
23.99
18.39
44.99
- -
48.21
Effective Tax Rate (%)
3.97
4.4
8.09
7.55
8.15
6.38
7.4
6.22
7.79
7.88
6.28
4.79
-17.68
10.94
3.86
- -
0.38
Profit Margin (%)
114,294
128,820
151,885
162,546
178,573
194,062
193,069
192,681
205,008
203,889
166,528
155,077
160,469
148,737
117,514
- -
106,419
Working Capital
- -
- -
- -
500
6,625
11,069
20,387
22,245
38,381
53,456
50,777
52,684
81,406
48,737
95,683
- -
92,490
LT Debt
241,985
250,700
264,116
282,357
315,733
337,259
364,673
365,842
376,364
411,615
440,359
437,412
370,736
414,739
380,935
- -
393,494
Total Equity
7.91
5.4
9.53
7.8
7.68
6.62
6.99
6.89
6.55
6.95
6.66
4.93
5.22
6.84
2.96
- -
0.92
Return on Invested Capital (%)
5.23
5.28
10.11
9.03
10.01
8.35
9.04
7.22
7.85
7.48
6.25
4.13
-10.91
7.34
3.33
- -
0.78
Return on Capital (%)
5.85
5.58
10.71
9.53
10.76
8.84
9.85
7.69
9.39
9.66
8.52
5.89
-15.35
10.92
4.72
- -
0.49
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
93,207
98,440
99,640
LT Borrowings
95,133
94,063
92,490
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
208
208
208
Market Capitalization
853,026
833,846
834,506

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
302,358
311,478
320,753
Cash, Cash Equivalents & STI
82,946
84,059
79,819
Accounts Receivable, Net
77,718
90,537
112,758
Inventories
119,705
122,482
111,575
Total Current Liabilities
200,787
212,226
214,334
Payables & Accruals
- -
- -
- -
ST Debt
93,207
98,440
99,640
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
82,310
85,905
88,380
84,403
340,997
2023
93,298
103,954
115,705
95,924
408,880
2024
85,046
95,734
121,062
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
37.98
43.62
82.9
- -
173.49
2023
27.09
43.51
23.36
- -
75.56
2024
-12.44
2.11
36.16
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
29.99
- -
34.99
- -
64.98
2023
35.51
- -
34.99
- -
70.8
2024
34.99
- -
- -
- -
- -
Similar Companies
Akzo Nobel N.V. (AKZOF)
Hindustan Organic Chemicals Limited (HOCL.BO)
Nan Ya Plastics Corporation (1303.TW)
Lanxess AG (LNXSF)
Yem Chio Co., Ltd. (4306.TW)
Beijing Media Corporation Limited (1000.HK)
Business
JSR Corporation engages in the development and supply of advanced polymer-based materials primarily for semiconductors, displays, life sciences, and plastics applications worldwide. Founded in 1957 and headquartered in Tokyo, Japan, the company operates through its Digital Solutions segment, which provides lithography materials including photoresists and multilayer materials, CMP materials such as slurries and cleaning solutions, packaging materials, and mounting materials; display materials encompassing those for color LCD panels, OLED displays, and functional coatings; and optical solutions featuring heat-resistant transparent resins, high-performance UV curable resins, films, and stereolithography systems. Its Life Sciences segment offers drug discovery and development services through contract development and manufacturing organizations (CDMO) and contract research organizations (CRO), bioprocess products like Protein A affinity chromatography resins including the newly launched Amsphere A+ in September 2024, in vitro diagnostic reagents, and research materials; the Plastics segment supplies synthetic resins such as ABS, AES, AS, and ASA for automotive parts, appliances, and building materials; while Other Businesses include acrylic and water-based emulsions, stain resistance products, and Holter ECG monitoring services. JSR maintains global operations with manufacturing and R&D facilities in Japan, the United States, Korea, Europe, and Asia. In recent developments, JSR completed the acquisition of Yamanaka Hutech Corporation in August 2024, making it a wholly-owned subsidiary to expand high-purity chemicals and semiconductor film-forming technologies; established a new photoresist R&D center in Japan's Kanto region and a production plant at JSR Micro Korea for metal oxide resists (MOR) with operations starting in 2026; announced the sale of its in vitro diagnostics division in April 2025 to sharpen focus on digital solutions; entered a joint research agreement with Illumi Medical in November 2024 for photomedical technologies and an alliance with Metagen Therapeutics in September 2024 for microbiome medicine manufacturing; formed a global agreement between Crown Bioscience and Shanghai Model Organism Center in June 2024; and delisted from the Tokyo Stock Exchange in 2024 following a tender offer by JICC-02 Co., Ltd., transitioning to private ownership while adopting the SPARKS strategic framework emphasizing semiconductor solutions, photoresist innovation, and advanced materials.